Supplementary Table 1.

Radiographic progression-free survival in East Asians and the other subjects

	East Asians		Overall but excluding East Asians
	Placebo (n=110)	Apalutamide (n=111)	Placebo (n=417)	Apalutamide (n=414)
Events, n (%)	40 (36.4)	23 (20.7)	191 (45.8)	111 (26.8)
Median rPFS, months (95% CI)	NE (18.40–NE)	NE (NE–NE)	21.98 (18.33–32.92)	NE (28.71–NE)
6 months rPFS rate (95% CI)	0.888 (0.811–0.935)	0.954 (0.892–0.980)	0.866 (0.829–0.895)	0.955 (0.929–0.971)
12 months rPFS rate (95% CI)	0.746 (0.650–0.820)	0.825 (0.737–0.886)	0.691 (0.643–0.734)	0.848 (0.808–0.880)
24 months rPFS rate (95% CI)	0.523 (0.393–0.638)	0.761 (0.660–0.836)	0.463 (0.403–0.521)	0.665 (0.603–0.720)
P a		0.0094		<0.0001
HR (95% CI)b		0.511 (0.305–0.856)		0.485 (0.383–0.613)

^aP value from the log-rank test, ^bHR from the proportional hazards model. HR <1 favors active treatment. The East Asian sub-population included the subjects from Japan, China, and South Korea. rPFS: radiographic progression-free survival; NE: not estimable; HR: hazard ratio; CI: confidence interval